Opinion/decision on a Paediatric investigation plan (PIP): Magnesium lactate dihydrate Tramadol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2022

Opinion/decision on a Paediatric investigation plan (PIP): Magnesium lactate dihydrate Tramadol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2022

Opinion/decision on a Paediatric investigation plan (PIP): N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), decision type: , therapeutic area: , PIP number: P/0275/2022

Opinion/decision on a Paediatric investigation plan (PIP): N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), decision type: , therapeutic area: , PIP number: P/0275/2022

Opinion/decision on a Paediatric investigation plan (PIP): nebivolol (hydrochloride),Amlodipine (besilate), decision type: , therapeutic area: , PIP number: P/0338/2022

Opinion/decision on a Paediatric investigation plan (PIP): nebivolol (hydrochloride),Amlodipine (besilate), decision type: , therapeutic area: , PIP number: P/0338/2022

Opinion/decision on a Paediatric investigation plan (PIP): nebivolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0276/2022

Opinion/decision on a Paediatric investigation plan (PIP): nebivolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0276/2022

Human medicines European public assessment report (EPAR): Mektovi, binimetinib, Melanoma, Date of authorisation: 20/09/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Mektovi, binimetinib, Melanoma, Date of authorisation: 20/09/2018, Revision: 7, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness